Eurofins Enhances Its Clinical and BioPharma Service Offering in Japan with Immune Repertoire Analysis Technology Through the Acquisition of Repertoire Genesis Inc.
May 31 2022 - 12:15AM
Business Wire
Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), a global scientific
leader in bioanalytical testing and clinical diagnostics testing,
announces the completion of the acquisition of a majority stake in
Repertoire Genesis Inc. (“RG”). RG owns a unique and proprietary
analytical platform, TCR/BCR (T Cell Receptor/B Cell Receptor)
repertoire profiling, that enables scientists to determine the
specific pathophysiological status of immune responses derived from
cancer, autoimmune diseases, transplants, and infectious diseases.
RG’s analytical platform is an important resource for
immune-related translational research, biomarker, diagnostics and
pharmaceutical development from discovery stage through to clinical
trials. The acquisition of RG will further expand Eurofins’ service
offering to the healthcare sector globally and strengthen its
unique service portfolio and position in the global bioanalytical
market.
RG, with over 20 staff based in its laboratory in Osaka, is
leading innovation in repertoire analysis, and is expected to
establish a leading position in the Japanese bioanalytical market
as a solution provider for immune-related diseases and research.
Since its establishment in 2014, RG has developed and offered
long-read TCR/BCR repertoire analysis based on novel bioinformatics
through a wide range of R&D activity from translational
research to clinical trials. RG has a master patent granted in
Japan, the United States, and Europe and was the first laboratory
accredited against ISO/IEC 17025 in the field of TCR/BCR repertoire
analysis.
Notes to Editors:
For more information, please visit www.eurofins.com
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in
food, environment, pharmaceutical and cosmetic product testing, and
in discovery pharmacology, forensics, advanced material sciences
and agroscience Contract Research services. Eurofins is also a
market leader in certain testing and laboratory services for
genomics, and in the support of clinical studies, as well as in
BioPharma Contract Development and Manufacturing. The Group also
has a rapidly developing presence in highly specialised and
molecular clinical diagnostic testing and in-vitro diagnostic
products.
With 58,000 staff across a decentralised and entrepreneurial
network of 900 laboratories in 54 countries, Eurofins offers a
portfolio of over 200,000 analytical methods to evaluate the
safety, identity, composition, authenticity, origin, traceability
and purity of a wide range of products, as well as providing
innovative clinical diagnostic testing services and in-vitro
diagnostic products.
The Group’s objective is to provide its customers with
high-quality services, innovative solutions and accurate results on
time. Eurofins is ideally positioned to support its clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
requirements of healthcare practitioners around the world.
In 2020 and 2021, Eurofins reacted quickly to meet the global
challenge of COVID-19, by creating the capacity to help over 20
million patients monthly who may have been impacted by the pandemic
with our testing products and our services and directly supporting
healthcare professionals working on the front line to fight the
virus. The Group has established widespread PCR testing
capabilities and has carried out over 40 million tests in its own
laboratories, is supporting the development of a number of vaccines
and has established its SAFER@WORK™ testing, monitoring and
consulting programmes to help ensure safer environments, travel and
events during COVID-19.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220530005227/en/
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024